CHAPEL EN LE FRITH, England, Jan. 9 /CNW/ - Peakdale Molecular Ltd a
leading provider in specialist chemistry services to the pharmaceutical
industry has announced today that they have successfully completed a GBP1m
round of equity funding which will enable Peakdale to continue the expansion
of its facilities in the UK to support its continued rapid growth.
The investors in this round were led by Solon Ventures LP, advised by
Solon Ventures Ltd, and were supported by a number of existing investors.
Commenting on the deal, Peakdale's Commercial Director Ray Fisher said:
"I am very grateful for being introduced to the team at Solon Ventures at such
an important time in Peakdale's history. With our plans for aggressive growth,
Solon's sector knowledge and desire to actively support such activities,
together we appear to have the ingredients of a perfect synergy."
Adding to this, Solon Ventures Ltd Managing Director Angus Whiteley said:
"We are delighted to be involved with Ray and his team at Peakdale in this
exciting stage of its development. With its excellent reputation and high
quality services, we believe Peakdale is very well placed to continue to
support the pharmaceutical and biotech industries in the future. We look
forward to playing an active role, based on our experience of the sector, in
helping the company achieve its growth and international aspirations."
About Peakdale Molecular
Peakdale Molecular was founded in 1992. Today the Company's customers
include the majority of the major global pharmaceutical companies and an
increasing number of biotechnology companies. Its teams of chemists combine
experience in pharmaceutical R&D and process development, medicinal chemistry,
parallel synthesis and fine chemicals to deliver unique chemistry solutions to
a range of drug discovery challenges.
The application of less commonly used chemistry, including high
temperature/pressure reactions, proprietary heterocyclic chemistry and
nucleoside synthesis, enables Peakdale's chemists to generate unique compounds
for drug discovery. Peakdale operates in several distinct markets providing
novel screening compounds, targeted screening libraries, catalogue
intermediates, custom synthesis and contract research. Further information
about the Company can be obtained at http://www.peakdale.com
About Solon Ventures LP
Solon Ventures LP is a Jersey-based limited partnership that invests in
private UK healthcare and technology companies. The fund is advised by Solon
Ventures Ltd, a UK company that advises GBP35m of venture capital investment
for a range of clients.
For further information:
For further information: Peakdale Molecular, Ray Fisher, Commercial
Director, Peakdale Molecular Ltd, Peakdale Science Park, Sheffield Road,
Chapel-en-le-Frith, High Peak, SK23 0PG, UK, Tel +44(0)1298-816700, Fax
+44(0)1298-816701; Angus Whiteley, Managing Director, Solon Ventures Ltd, 24
Old Bond Street, London, W1S 4AW, UK, Tel +44(0)20-7535-4912, Fax